Webinar: eCTD Submission Different Strategies: In-house vs. Outsourcing
eCTD Submission Strategies, including outsourcing, are influenced by varying requirements in various regions and countries. That and diverse technical resources by companies often lead to various regulatory strategies. Thus, the questions arises: how to choose the best tactics for eCTD submission that your needs?
The purpose of this webinar is to discuss the different approaches to prepare eCTD submissions, its requirements, technical resources, and process validation.
You will learn about:
1. Requirements for eCTD
- Different forms of eCTD used in EU vs. EAEU eCTD
- Legislation framework
- Regions and countries following the eCTD
2. Different approaches to prepare eCTD submissions: In-house vs. Outsourcing
- Advantages of eCTD submission outsourcing strategies vs. in-house management:
- Optimization of resources with proper experience
- Increased business continuity
- Cost optimization
3. Technical resources
- Software and networks
- Document and project management
- Potential challenges
4. How to validate submission to achieve compliance and high quality
- Tips and tricks
Registering a new product?
Make use of our experts to enter new markets. Explore your options in an informal chat with one of our experts.
Who Should Attend? Professionals from the following fields:
- Regulatory Managers
- Regulatory Strategy Managers
- RA Partnerships Operations Manager
- QA Managers supporting RA
- RA Healthcare Compliance Managers
Duration: 25 min.
Speaker: Head of Global Regulatory Affairs, Olga Bernardova, MSc, who will share her expertise regarding eCTD submissions.
Olga Bernardova, MSc
Head of Global Regulatory Affairs
Other content that might interest you:
Proper Publicizing in CEECs – Path to Successful Social Media Commercials
With the growth of social media network users all over the world, there is no doubt that one of the most widely used channels for promoting is social media. Statistics show that Facebook and Instagram were used actively with more than 3.4 billion people daily by January 2020. Therefore, since medical devices and over-the-counter medicines are being more often promoted by commercials on social media nowadays, there is a greater risk of hidden or misleading advertisements.
How Mergers and Acquisitions of Pharma Companies affect Regulatory Affairs?
It is easy to notice that Mergers and Acquisitions (M&A) have become a frequent occurrence in the Pharmaceutical industry, especially during the previous decades. Pharma industry is one of the leading industries in the number of M&A and the size of investments for such transitions. The value for M&A in the pharmaceutical sector was $221 billion in the first half of the year 2015. In 2019, the worth of pharma companies M&A activities have reached $357 billion.
CMC: Best Practice in Effective IND and IMPD writing
This time we will focus on technical writing and preparation for it. Also, I will provide some primary recommendations for CMC writers. The IND/IMPD being a regulatory document, has the same structure as CTD dossier. However, it includes remarkably less information on the developmental product, yet, the technical writers should understand that they will need to prepare the document in the way to reflect the actual production process and control further during the development in the later clinical phases.
